Bio-Techne Corporation

NasdaqGS:TECH Stock Report

Market Cap: US$7.9b

Bio-Techne Past Earnings Performance

Past criteria checks 0/6

Bio-Techne's earnings have been declining at an average annual rate of -2.2%, while the Life Sciences industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 9.3% per year. Bio-Techne's return on equity is 6.5%, and it has net margins of 10.9%.

Key information

-2.2%

Earnings growth rate

-2.9%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate9.3%
Return on equity6.5%
Net Margin10.9%
Last Earnings Update31 Mar 2025

Recent past performance updates

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Recent updates

Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Apr 28
Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Market Participants Recognise Bio-Techne Corporation's (NASDAQ:TECH) Earnings

Apr 07
Market Participants Recognise Bio-Techne Corporation's (NASDAQ:TECH) Earnings

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Feb 27

Here's Why Bio-Techne (NASDAQ:TECH) Can Manage Its Debt Responsibly

Jan 21
Here's Why Bio-Techne (NASDAQ:TECH) Can Manage Its Debt Responsibly

At US$71.48, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jan 03
At US$71.48, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

Dec 15
Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Sep 11
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Aug 24
Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
author-image

Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges

Aug 22 Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jun 09
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

Revenue & Expenses Breakdown

How Bio-Techne makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:TECH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 251,20913248897
31 Dec 241,19615844899
30 Sep 241,17215143397
30 Jun 241,15916842997
31 Mar 241,15420341796
31 Dec 231,14522442693
30 Sep 231,14424740793
30 Jun 231,13728539792
31 Mar 231,12427141592
31 Dec 221,12026239091
30 Sep 221,11829240089
30 Jun 221,10627239287
31 Mar 221,07622536185
31 Dec 211,03021035080
30 Sep 2198517733476
30 Jun 2193114031271
31 Mar 2184818429667
31 Dec 2079917528266
30 Sep 2076024827165
30 Jun 2073922926765
31 Mar 2075518727365
31 Dec 1974519527164
30 Sep 197349326664
30 Jun 197149626262
31 Mar 1970312125760
31 Dec 186829624458
30 Sep 1866112823257
30 Jun 1864312621655
31 Mar 1861911219455
31 Dec 1759911418755
30 Sep 175777318354
30 Jun 175637617554
31 Mar 175417417051
31 Dec 165288215849
30 Sep 1651710114547
30 Jun 1649910413845
31 Mar 1648210513044
31 Dec 154659912544
30 Sep 1545610712143
30 Jun 1545210811541
31 Mar 1542710810138
31 Dec 144081168634
30 Sep 143801077132
30 Jun 143581116031

Quality Earnings: TECH has a large one-off loss of $45.0M impacting its last 12 months of financial results to 31st March, 2025.

Growing Profit Margin: TECH's current net profit margins (10.9%) are lower than last year (17.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TECH's earnings have declined by 2.2% per year over the past 5 years.

Accelerating Growth: TECH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TECH had negative earnings growth (-35.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.7%).


Return on Equity

High ROE: TECH's Return on Equity (6.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/09 22:43
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Techne Corporation is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird